Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER_GOV × Hepatitis C × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

OTHER 2 OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 14 Stomach Neoplasms 11 Uterine Cervical Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 8 Ovarian Neoplasms 7 Esophageal Neoplasms 7 Fallopian Tube Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Recurrence 4 Neoplasm Metastasis 4 Head and Neck Neoplasms 4 Colorectal Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Hepatocellular 4 Rectal Neoplasms 3 Nasopharyngeal Carcinoma 3 Multiple Myeloma 3 Mouth Neoplasms 3 Lymphoma, Non-Hodgkin 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Glioblastoma 3 Esophageal Squamous Cell Carcinoma 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Polycystic Ovary Syndrome 2 Peripheral Nervous System Diseases 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lung Neoplasms 2

Interventions

elbasvir-grazoprevir drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04546802 2020-09-14

HATCHeT

Bayside Health

Phase 3 Withdrawn

Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡